BioSpace News Archive

Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Orphan Drug Designation in the U.S. for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the start of the final stage of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19.

Diversigen, Inc., a subsidiary of OraSure Technologies Inc., and Nom Nom™, a direct-to-consumer pet health brand, announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services.

Cardinal Health announced that it is sending an irrevocable notice of early redemption to the holders of the Company’s $500 million 4.625% notes due 2020.

Solid Biosciences Inc. announced that, due to the public health impact of the novel coronavirus outbreak and governmental restrictions limiting the number of people who may gather together, its 2020 Annual Meeting of Stockholders, to be held on Tuesday, June 16, 2020 at 8:00 a.m.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, provided a business update and reported financial results for the first quarter of 2020.

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, posted notice of its Annual General Meeting to shareholders, which can be viewed and downloaded from www.autolus.com.

Geron Corporation, a late-stage clinical biopharmaceutical company, announced the pricing of its previously announced underwritten public offering of 107,049,375 shares of its common stock and pre-funded warrants to purchase 8,335,239 shares of common stock, together with accompanying warrants to purchase 57,692,307 shares of common stock.

Management to host webcast and conference call to review interim Phase 1 data and provide a pipeline update at 4 p.m. ET /1 p.m. PT on May 29, 2020

Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced its financial results for the first quarter ended March 31, 2020. First Quarter 2020 Highlights Net Revenues for the first quarter of 2020 decreased to $7.4 million compared to $13.1 million in the same quarter of the prior year. The $5.7 million decrease was driven primarily by a $3.8 million decrease in US Teligent label products relat